| 本文已被：浏览 247次 下载 266次 |
码上扫一扫！ |
| 不同给药途径治疗早产儿动脉导管未闭有效性和安全性的 Meta 分析 |
| 向祾祾,申悦,孙建,华子瑜 |
|
|
| (重庆医科大学附属儿童医院,儿童发育疾病研究教育部重点实验室,国家儿童健康与疾病临
床医学研究中心,儿童发育重大疾病国家国际科技合作基地,儿科学重庆市重点实验室,重庆 400014) |
|
| 摘要: |
| 目的:系统评价不同药物给药途径治疗早产儿动脉导管未闭的有效性和安全性。 方法:计算机检索 PubMed、EMBase、the Cochrane Library、万方、中国知网、维普数据库,检索时间为建库至 2021 年 9 月 6 日。 纳入采用口服用药(试验组)和静脉用药(对照组)治疗早产儿动脉导管未闭的随机对照试验,使用 RevMan 5. 3 软件进行分析。 结果:最终纳入 5 篇文献进行 Meta 分析,共 330 例患儿。 Meta 分析结果显示,口服用药组动脉导管闭合率与静脉用药组比较差异无统计学意义(RR = 1. 04,95%CI0. 96~1. 12,P = 0. 39),两组患儿相关不良反应发生率、病死率及住院时间比较差异无统计学意义(P>0. 05)。 结论:当前证据表明,口服用药与静脉用药治疗 PDA 的有效性和安全性无明显差异。 受研究数量和质量的影响,仍需开展更多高质量的随机对照研究探讨不同给药途径对不同特征、用药时机的早产儿 PDA 闭合的影响。 |
| 关键词: 口服用药 静脉用药 早产儿 动脉导管未闭 Meta 分析 |
| DOI：10.13407/j.cnki.jpp.1672-108X.2023.07.009 |
|
| 基金项目: |
|
| Meta-Analysis of Efficacy and Safety of Different Drug Administration Routes for the Treatment of Premature Infants with Patent Ductus Arteriosus |
| Xiang Lingling, Shen Yue, Sun Jian, Hua Ziyu |
| (Children’ s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China) |
| Abstract: |
| Objective: To systematically evaluate the efficacy and safety of different drug administration routes for the treatment of premature infants with patent ductus arteriosus. Methods: PubMed, EMBase, the Cochrane Library, Wanfang, CNKI and VIP databases were retrieved from the establishment of the database to Sept. 6th , 2021. Randomized controlled trial with oral administration (experimental group) and intravenous administration ( control group) for the treatment of ductus arteriosus in preterm infants was included. Meta-analysis was conducted with RevMan 5. 3 software. Results: Totally 5 articles were enrolled, including 330 patients. Meta-analysis showed that there was no significant difference in the arterial duct closure rate between the oral administration group and
the intravenous administration group (RR= 1. 04, 95% CI from 0. 96 to 1. 12, P = 0. 39). There was no significant difference in the incidence of related adverse drug reactions, mortality and length of stay between two groups (P>0. 05). Conclusion: Current evidence suggests that there is no significant difference in the efficacy and safety of oral versus intravenous administration for the treatment of PDA. Due to the number and quality of studies, more high-quality randomized controlled studies are still needed to explore the effects of different routes of administration on PDA closure in preterm infants with different characteristics and timing of administration. |
| Key words: oral administration intravenous administration premature infants patent ductus arteriosus Meta-analysis |
